Neulasta

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Reuters
Coherus Biosciences
Amgen
biosimilars
Neulasta
Flag link:
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Endpoints
Coherus
Neulasta
Mylan
biosimilars
Amgen
Flag link:
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts
Biopharma Dive
Amgen
Neulasta
biosimilars
Flag link:
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Amgen
biosimilars
Neulasta
Alexion
M&A
Flag link:
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Fierce Pharma
FDA
Fulphila
Mylan Labs
biosimilars
Amgen
Neulasta
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
CP Wire
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
Coherus Biosciences
Neulasta
CHS-1701
Mylan
Biocon
Flag link:
What to Expect From Amgen, Inc. in 2018
What to Expect From Amgen, Inc. in 2018
Motley Fool
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Flag link:
Will 2018 Be Amgen Inc.'s Best Year Yet?
Will 2018 Be Amgen Inc.'s Best Year Yet?
Motley Fool
Amgen
Enbrel
Aranesp
Neulasta
Epogen
Flag link:
The 2018 biosimilar litigation landscape: A primer
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Flag link:
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Novartis
Neulasta
biosimilars
Amgen
Sandoz
FDA
Flag link:
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
Yahoo/Zacks.com
Nektar
AstraZeneca
Movantik
Onzeald
UCB Pharma
Cimzia
Amgen
Neulasta
Flag link:
Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL
Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL
Fierce Pharma
Mylan Labs
Biocon
Amgen
Neulasta
CRL
FDA
biosimilars
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link:
Coherus cuts staff after FDA red light
Coherus cuts staff after FDA red light
BioPharma Dive
Coherus Biosciences
layoffs
FDA
biosimilars
Amgen
Neulasta
Flag link:
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Amgen
Novartis
Supreme Court
biosimilars
Neulasta
FDA
Coherus Biosciences
Flag link:
Amgen accuses would-be copycat Coherus of stealing its Neulasta secrets
Amgen accuses would-be copycat Coherus of stealing its Neulasta secrets
Fierce Pharma
Coherus Biosciences
Amgen
Neulasta
biosimilars
Flag link:
Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
Novartis silently yanks a troubled biosimilar application; Chinese antibody developer draws $39M round
Endpoints
Novartis
biosimilars
Zioxtenzo
Europe
Amgen
Neulasta
China
Flag link:
Amgen Products Threatened by Court Losses
Amgen Products Threatened by Court Losses
Investopedia
Amgen
Apobiologix
Neupogen
Grastofil
Neulasta
Lapelga
biosimilars
patents
Flag link:
U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta
U.S. FDA knocks back Novartis copy of Amgen's drug Neulasta
Yahoo/Reuters
FDA
Novartis
biosimilars
Amgen
Neulasta
Flag link:

Pages